Clinical efficacy of MEK inhibitor monotherapy in MPNST has not been reported to date, but a Phase 2 trial is testing the combination of selumetinib and sirolimus (mTOR inhibitor) in MPNST (NCT03433183). The gene discussed is MTOR; the disease is malignant peripheral nerve sheath tumor.